Literature DB >> 15231742

Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome.

Pascal Kahlem1, Marc Sultan, Ralf Herwig, Matthias Steinfath, Daniela Balzereit, Barbara Eppens, Nidhi G Saran, Mathew T Pletcher, Sarah T South, Gail Stetten, Hans Lehrach, Roger H Reeves, Marie-Laure Yaspo.   

Abstract

Human trisomy 21, which results in Down syndrome (DS), is one of the most complicated congenital genetic anomalies compatible with life, yet little is known about the molecular basis of DS. It is generally accepted that chromosome 21 (Chr21) transcripts are overexpressed by about 50% in cells with an extra copy of this chromosome. However, this assumption is difficult to test in humans due to limited access to tissues, and direct support for this idea is available for only a few Chr21 genes or in a limited number of tissues. The Ts65Dn mouse is widely used as a model for studies of DS because it is at dosage imbalance for the orthologs of about half of the 284 Chr21 genes. Ts65Dn mice have several features that directly parallel developmental anomalies of DS. Here we compared the expression of 136 mouse orthologs of Chr21 genes in nine tissues of the trisomic and euploid mice. Nearly all of the 77 genes which are at dosage imbalance in Ts65Dn showed increased transcript levels in the tested tissues, providing direct support for a simple model of increased transcription proportional to the gene copy number. However, several genes escaped this rule, suggesting that they may be controlled by additional tissue-specific regulatory mechanisms revealed in the trisomic situation. Copyright 2004 Cold Spring Harbor Laboratory Press ISSN

Entities:  

Mesh:

Year:  2004        PMID: 15231742      PMCID: PMC442140          DOI: 10.1101/gr.1951304

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  34 in total

Review 1.  Too much of a good thing: mechanisms of gene action in Down syndrome.

Authors:  R H Reeves; L L Baxter; J T Richtsmeier
Journal:  Trends Genet       Date:  2001-02       Impact factor: 11.639

2.  Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays.

Authors:  R Miki; K Kadota; H Bono; Y Mizuno; Y Tomaru; P Carninci; M Itoh; K Shibata; J Kawai; H Konno; S Watanabe; K Sato; Y Tokusumi; N Kikuchi; Y Ishii; Y Hamaguchi; I Nishizuka; H Goto; H Nitanda; S Satomi; A Yoshiki; M Kusakabe; J L DeRisi; M B Eisen; V R Iyer; P O Brown; M Muramatsu; H Shimada; Y Okazaki; Y Hayashizaki
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Statistical evaluation of differential expression on cDNA nylon arrays with replicated experiments.

Authors:  R Herwig; P Aanstad; M Clark; H Lehrach
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

4.  Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain.

Authors:  Rong Mao; Carol L Zielke; H Ronald Zielke; Jonathan Pevsner
Journal:  Genomics       Date:  2003-05       Impact factor: 5.736

5.  The promoter of the long variant of collagen XVIII, the precursor of endostatin, contains liver-specific regulatory elements.

Authors:  J Liétard; N Théret; M Rehn; O Musso; D Dargère; T Pihlajaniemi; B Clément
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

6.  Mutation analysis of SYNJ1: a possible candidate gene for chromosome 21q22-linked bipolar disorder.

Authors:  T Saito; F Guan; D F Papolos; S Lau; M Klein; C S Fann; H M Lachman
Journal:  Mol Psychiatry       Date:  2001-07       Impact factor: 15.992

7.  Ts65Dn -- localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome.

Authors:  E C Akeson; J P Lambert; S Narayanswami; K Gardiner; L J Bechtel; M T Davisson
Journal:  Cytogenet Cell Genet       Date:  2001

8.  The mouse brain transcriptome by SAGE: differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals.

Authors:  R Chrast; H S Scott; M P Papasavvas; C Rossier; E S Antonarakis; C Barras; M T Davisson; C Schmidt; X Estivill; M Dierssen; M Pritchard; S E Antonarakis
Journal:  Genome Res       Date:  2000-12       Impact factor: 9.043

9.  Automated image analysis for array hybridization experiments.

Authors:  M Steinfath; W Wruck; H Seidel; H Lehrach; U Radelof; J O'Brien
Journal:  Bioinformatics       Date:  2001-07       Impact factor: 6.937

10.  Developmental expression of the SH3BGR gene, mapping to the Down syndrome heart critical region.

Authors:  A Egeo; R Di Lisi1; C Sandri; M Mazzocco; M Lapide; S Schiaffino; P Scartezzini
Journal:  Mech Dev       Date:  2000-02       Impact factor: 1.882

View more
  102 in total

Review 1.  Trisomy 21 and early brain development.

Authors:  Tarik F Haydar; Roger H Reeves
Journal:  Trends Neurosci       Date:  2011-12-09       Impact factor: 13.837

2.  Overexpression of amyloid-β protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade.

Authors:  Matthew G Bartley; Kristin Marquardt; Danielle Kirchhof; Heather M Wilkins; David Patterson; Daniel A Linseman
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Ohnologs in the human genome are dosage balanced and frequently associated with disease.

Authors:  Takashi Makino; Aoife McLysaght
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

4.  Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn.

Authors:  Laura G Reinholdt; Yueming Ding; Griffith J Gilbert; Griffith T Gilbert; Anne Czechanski; Jeffrey P Solzak; Randall J Roper; Mark T Johnson; Leah Rae Donahue; Cathleen Lutz; Muriel T Davisson
Journal:  Mamm Genome       Date:  2011-09-28       Impact factor: 2.957

5.  Submicroscopic deletion in patients with Williams-Beuren syndrome influences expression levels of the nonhemizygous flanking genes.

Authors:  Giuseppe Merla; Cédric Howald; Charlotte N Henrichsen; Robert Lyle; Carine Wyss; Marie-Thérèse Zabot; Stylianos E Antonarakis; Alexandre Reymond
Journal:  Am J Hum Genet       Date:  2006-06-23       Impact factor: 11.025

Review 6.  The cognitive phenotype of Down syndrome: insights from intracellular network analysis.

Authors:  Avi Ma'ayan; Katheleen Gardiner; Ravi Iyengar
Journal:  NeuroRx       Date:  2006-07

7.  Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21.

Authors:  Robert Lyle; Frédérique Béna; Sarantis Gagos; Corinne Gehrig; Gipsy Lopez; Albert Schinzel; James Lespinasse; Armand Bottani; Sophie Dahoun; Laurence Taine; Martine Doco-Fenzy; Pascale Cornillet-Lefèbvre; Anna Pelet; Stanislas Lyonnet; Annick Toutain; Laurence Colleaux; Jürgen Horst; Ingo Kennerknecht; Nobuaki Wakamatsu; Maria Descartes; Judy C Franklin; Lina Florentin-Arar; Sophia Kitsiou; Emilie Aït Yahya-Graison; Maher Costantine; Pierre-Marie Sinet; Jean M Delabar; Stylianos E Antonarakis
Journal:  Eur J Hum Genet       Date:  2008-11-12       Impact factor: 4.246

8.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

9.  Segmental trisomy of chromosome 17: a mouse model of human aneuploidy syndromes.

Authors:  Tomás Vacík; Michael Ort; Sona Gregorová; Petr Strnad; Radek Blatny; Nathalie Conte; Allan Bradley; Jan Bures; Jirí Forejt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-08       Impact factor: 11.205

10.  Aneuploidy causes tissue-specific qualitative changes in global gene expression patterns in maize.

Authors:  Irina Makarevitch; Carolyn Harris
Journal:  Plant Physiol       Date:  2009-12-11       Impact factor: 8.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.